suberoyl bis-hydroxamic acid has been researched along with valproic acid in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burnett, R; Gottesfeld, JM; Herman, D; Jenssen, K; Perlman, SL; Soragni, E | 1 |
| Forgione, M; Hailu, GS; Mai, A; Robaa, D; Rotili, D; Sippl, W | 1 |
| Cassell, M; Lindsay, DS; Mitchell, SM; Reilly, CM; Strobl, JS | 1 |
| Europe-Finner, GN; Hehir, MP; Morrison, JJ; Moynihan, AT; Robson, SC; Sharkey, AM | 1 |
| Adler, JT; Chen, H; Hottinger, DG; Kunnimalaiyaan, M | 3 |
| Chen, H; Ning, L; Xiao, X | 1 |
| Chen, F; Dai, J; Ji, C; Li, J; Ma, D; Qu, X; Shao, N; Sun, X; Zou, J | 1 |
| Guo, Y; Ji, C; Lu, T; Ma, D; Shao, N; Wang, J | 1 |
1 review(s) available for suberoyl bis-hydroxamic acid and valproic acid
| Article | Year |
|---|---|
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
Topics: Animals; Antiparasitic Agents; Drug Repositioning; Helminth Proteins; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leishmania; Plasmodium; Protozoan Proteins; Schistosoma; Toxoplasma; Trypanosoma | 2017 |
9 other study(ies) available for suberoyl bis-hydroxamic acid and valproic acid
| Article | Year |
|---|---|
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
Topics: Acetylation; Alleles; Anilides; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Frataxin; Friedreich Ataxia; Gene Expression Regulation; Gene Silencing; HeLa Cells; Heterochromatin; Histone Deacetylase Inhibitors; Histones; Humans; Iron-Binding Proteins; Molecular Structure; RNA, Messenger; Transcription, Genetic | 2006 |
Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.
Topics: Animals; Antiprotozoal Agents; Butyrates; Cattle; Cell Line; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Hydroxylamines; Inhibitory Concentration 50; Niacinamide; Parasitic Sensitivity Tests; Phenylbutyrates; Quinolines; Toxoplasma; Valproic Acid; Vitamin B Complex; Vorinostat | 2007 |
Histone deacetylase inhibitors and a functional potent inhibitory effect on human uterine contractility.
Topics: Adult; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; Oxytocics; Oxytocin; Pregnancy; Protein Synthesis Inhibitors; Uterine Contraction; Valproic Acid | 2008 |
Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoid Tumor; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromogranin A; Enzyme Inhibitors; Gastrointestinal Neoplasms; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoglobulin J Recombination Signal Sequence-Binding Protein; Lithium Chloride; Luciferases; Lung Neoplasms; Receptor, Notch1; Valproic Acid | 2009 |
Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells.
Topics: Animals; Apoptosis; Cell Proliferation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Hydroxamic Acids; PC12 Cells; Rats; Receptor, Notch1; Up-Regulation; Valproic Acid | 2008 |
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
Topics: Adenocarcinoma, Follicular; Blotting, Western; Carcinoma, Papillary; Cell Cycle; Cell Proliferation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Plasmids; Receptor, Notch1; Thyroid Neoplasms; Transfection; Valproic Acid | 2009 |
Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride.
Topics: Cell Division; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lithium Chloride; Receptor, Notch1; Thyroid Neoplasms; Tumor Cells, Cultured; Up-Regulation; Valproic Acid | 2010 |
Hyper-activation of WNT/β-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia.
Topics: Apoptosis; beta Catenin; Blotting, Western; Caspase 3; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Flow Cytometry; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunohistochemistry; Jurkat Cells; Poly(ADP-ribose) Polymerases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Valproic Acid; Wnt Proteins | 2012 |
Notch1 signaling is irresponsible to the anti-leukemic effect of HDACis in B-ALL Nalm-6 cells.
Topics: Acetylation; Apoptosis; B-Lymphocytes; Cell Division; Cell Line, Tumor; Chromatin Assembly and Disassembly; Drug Screening Assays, Antitumor; G1 Phase; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Processing, Post-Translational; Receptor, Notch1; Valproic Acid | 2013 |